Shots:

• The P-III JUNIPERA study evaluates secukinumab (75/150 mg) vs PBO in 86 children & adolescents aged 2-17yrs. with a confirmed diagnosis of JPsA or ERA
• The results showed a 72% reduction in risk of flare, 30% patients showed an improvement with Cosentyx @1wks., improved disease activity @ 2yrs., 90% achieved JIA ACR 30 at an end of 1^st treatment (12wks.) 35% achieved JIA ACR inactive disease status @12wks., safety was consistent with a known
• The company has filed regulatory submissions of Cosentyx for ERA & JPsA in the EU & US with an expected EMA & US FDA's decisions in coming mos. If Cosentyx is approved, it will be 1^st biologic treatment for ERA in the US

  Ref: Novartis | Image: Novartis